Abstract | OBJECTIVE: METHODS: A retrospective review of prospectively collected data on 213 consecutive patients who underwent single- or double- lung transplantation was performed. Ninety-nine patients, who received aprotinin, were compared with 114 patients who did not. The main outcome variables analysed were development of primary graft dysfunction, renal impairment and mortality. RESULTS:
Aprotinin was associated with a significantly increased risk of PGD in the first 48 h postoperatively (p=0.01). CONCLUSIONS: In conclusion, although the benefits of aprotinin on blood loss are well established, this study does not provide support for the use of aprotinin to reduce PGD in lung transplantation and indicates that aprotinin may in fact have a detrimental effect.
|
Authors | Silvana F Marasco, David Pilcher, Takahiro Oto, Wenly Chang, Anne Griffiths, Vince Pellegrino, Justin Chan, Michael Bailey |
Journal | European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
(Eur J Cardiothorac Surg)
Vol. 37
Issue 2
Pg. 420-5
(Feb 2010)
ISSN: 1873-734X [Electronic] Germany |
PMID | 19767212
(Publication Type: Journal Article)
|
Copyright | Crown Copyright 2009. Published by Elsevier B.V. All rights reserved. |
Chemical References |
- Hemostatics
- Serine Proteinase Inhibitors
- Aprotinin
- Creatinine
|
Topics |
- Adult
- Aprotinin
(adverse effects)
- Creatinine
(blood)
- Epidemiologic Methods
- Female
- Hemostasis, Surgical
(adverse effects, methods)
- Hemostatics
(adverse effects)
- Humans
- Kidney
(physiopathology)
- Lung Transplantation
(adverse effects)
- Male
- Middle Aged
- Primary Graft Dysfunction
(chemically induced, physiopathology)
- Serine Proteinase Inhibitors
(adverse effects)
- Young Adult
|